Mantra Bio announced it has raised $9 million in a Series A-2 financing to advance the development of its lead targeted exosome therapeutics program.

New investor, Samsung Securities, joined existing investors, including 8VC, Viking Global Investors, Illumina, BoxGroup and Allen & Company in the financing round. The company's overall Series A funding, including a $25 million Series A-1, totals $34 million.